[{"orgOrder":0,"company":"Medivir","sponsor":"Shijiazhuang Yuanmai Biotechnology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medivir and Shijiazhuang Yuanmai Biotechnology Sign Licensing Agreement Regarding Manufacturing and Sales of Xerclear\u00ae in China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Aciclovir","moa":"DNA polymerase","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Medivir","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"","amount2New":0,"dosageForm":"Cream","sponsorNew":"Medivir \/ Shijiazhuang Yuanmai Biotechnology","highestDevelopmentStatusID":"12","companyTruncated":"Medivir \/ .."},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"$3.5 million","newsHeadline":"Eton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi\u00ae Sprinkle","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diurnal Group","amount2":0.01,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Steroid","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Diurnal Gr.."},{"orgOrder":0,"company":"AVM Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AVM Biotechnology Awarded SBIR Phase I Grant from National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Stem Cell engraftment","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AVM Biotechnology","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AVM Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AVM Biotec.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharma Gets FDA Approval of Orphan Drug ALKINDI\u00ae SPRINKLE as Replacement Therapy in Children with Adrenocortical Insufficiency","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Diurnal Group","sponsor":"EffRx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EffRx Pharma Signs a License Agreement with Diurnal for the Registration and Commercialization of Alkindi\u00ae","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ EffRx","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Gr.."},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Global Coalition for Adaptive Research, Amgen, and Eisai Announce First Patient Enrolled in International COVID-19 Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Global Coalition for Adaptive Research","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","productSubType":"HPAPI","amount2New":0,"dosageForm":"","sponsorNew":"Global Coalition for Adaptive Research \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Global Coa.."},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI\u00ae SPRINKLE","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Acquisition","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Gr.."},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diurnal Seeks UK MHRA Marketing Approval for Chronocort to Treat Patients with Rare Condition Congenital Adrenal Hyperplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Gr.."},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Citrine","pharmaFlowCategory":"D","amount":"$13.2 million","upfrontCash":"$0.5 million","newsHeadline":"Citrine Medicine Announces Strategic Partnership with Diurnal To Bring Alkindi\u00ae To China For Use In Pediatric Congenital Adrenal Hyperplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Diurnal Group","amount2":0.01,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Citrine","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Gr.."},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diurnal Group plc - Chronocort\u00ae Phase 3 and Safety Extension Study Results Published in JCEM","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Gr.."},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Citrine Medicine","pharmaFlowCategory":"D","amount":"$2.2 million","upfrontCash":"$1.0 million","newsHeadline":"Diurnal Triggers $1.25m in Milestone Payments from Citrine Medicine","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Partnership","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Citrine Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Gr.."},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diurnal Group plc - Diurnal receives European Commission approval for Efmody\u00ae","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Gr.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Crossject","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"CROSSJECT: License agreement in the United States and Canada with Eton Pharmaceuticals for ZENEO\u00ae Hydrocortisone","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Eton Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Eton Pharmaceuticals \/ Crossject","highestDevelopmentStatusID":"12","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antares Pharma FDA Acceptance of IND Application for ATRS-1902","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","year":"2021","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Antares Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antares Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antares Ph.."},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Diurnal Group launches Efmody in UK to Treat Patients with Rare Condition Congenital Adrenal Hyperplasia","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"Diurnal Group","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Diurnal Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Diurnal Gr.."},{"orgOrder":0,"company":"Tolmar","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eton Pharmaceuticals Announces Co-Promotion Agreement with Tolmar Pharmaceuticals for ALKINDI SPRINKLE\u00ae","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Agreement","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Tolmar","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tolmar \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Tolmar \/ E.."},{"orgOrder":0,"company":"Antares Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescue","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2022","year":"2022","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I","graph3":"Antares Pharma","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Antares Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Antares Ph.."},{"orgOrder":0,"company":"EffRx Pharmaceuticals","sponsor":"Diurnal Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"EffRx Pharmaceuticals Signs Exclusive License Agreement With Diurnal for the Registration and Commercialization of Efmody\u00ae in Switzerland","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2022","year":"2022","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved","graph3":"EffRx Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Genetic Disease","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","productSubType":"Steroid","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EffRx Pharmaceuticals \/ Diurnal Group","highestDevelopmentStatusID":"12","companyTruncated":"EffRx Phar.."},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov Database","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Not Applicable","leadProduct":"Dexamethasone","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Orion Corporation","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Orion Corporation \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"Orion Corp.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase III","graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Endocrinology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","productSubType":"Steroid","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eton Pharm.."},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eton Pharmaceuticals\u2019 ET-400 NDA Accepted by FDA","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2024","year":"2024","type":"Not Applicable","leadProduct":"Hydrocortisone","moa":"","url1":"","url2":"","graph1":null,"graph2":null,"graph3":"Eton Pharmaceuticals","amount2":0,"therapeuticAreaNew":null,"highestDevelopmentStatusNew":null,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Eton Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Eton Pharm.."}]
Find Clinical Drug Pipeline Developments & Deals for Retef
Details :
ODM-208 (or MK-5684) is an investigational oral, non-steroidal and selective inhibitor of the CYP11A1 enzyme discovered and developed by Orion for the treatment of hormone-dependent cancers, such as metas...
Details :
ET-400 is Eton’s proprietary patented formulation of hydrocortisone oral solution. Company has submitted NDA for ET-400 use in endocrine system disorders.
Details :
ET-400 is Eton’s proprietary patented formulation of hydrocortisone oral solution. Company has submitted NDA for ET-400 use in endocrine system disorders.
Details :
Efmody® is a modified-release preparation of hydrocortisone that has been specifically designed for the treatment of patients with CAH, a rare condition caused by a genetic deficiency of adrenal enzymes.
Details :
The results of the Phase I study met its primary objective showing ATRS-1902 delivered a comparable pharmacokinetic profile and also demonstrated that ATRS-1902 was safe and well-tolerated for the treatme...
Details :
Under terms of the agreement, Tolmar’s sales force will promote ALKINDI SPRINKLE® to their pediatric endocrinology targets alongside FENSOLVI®. ALKINDI SPRINKLE® (hydrocortisone) oral granules is FDA...
Details :
Efmody® is a preparation of hydrocortisone that has been specifically designed for patients with CAH, a rare condition caused by deficiency of adrenal enzymes, most commonly 21-hydroxylase.
Details :
The active IND enables Antares to initiate a Phase 1 clinical study for ATRS-1902 for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using a novel propri...
Details :
The ready to use ZENEO® Hydrocortisone will provide a 2-step rescue kit developed for a simple and intuitive autoinjection even by non healthcare professionals.
Details :
The $1.25 million milestone payment has been triggered as a result of the recent European Commission’s approval for Efmody® (hydrocortisone modified-release hard capsules) and the attainment by Citrin...
Market Place
Reset All
